Ginkgo Bioworks Reports First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Ginkgo Bioworks (DNA) Q1 Revenues Beat; Guides Higher
May 16, 2022 4:02 PM EDTGinkgo Bioworks (NYSE: DNA) reported Q1 revenue $168 million versus the consensus estimate of $105.68 million.
GUIDANCE:
Ginkgo Bioworks sees FY2022 revenue of $375-390 million, versus the consensus of $333 million.
For earnings history and earnings-related data on Ginkgo Bioworks (DNA) click here.
... More